「sme」の検索結果

Performs a structured pre‑prescription evaluation of mental/psychological status, prior diabetes self‑care adherence, willingness/interest in CSII, and availability for follow‑up visits. Triggers include: 'Evaluating pump candidacy', 'Pre‑pump checklist: psych, adherence, motivation, follow-up'.

日本語の概要は準備中です。原文の説明を表示しています。

This skill guides evaluation of venous thromboembolism (VTE) risk factors in Cushing's syndrome patients to prevent thrombotic complications. Use when assessing a CS patient for thrombotic risk, especially perioperatively; triggers include preoperative assessment, postoperative period (within 4-6 weeks), or presence of CS with additional risk factors such as prior VTE, immobilization, malignancy, or estrogen use.

日本語の概要は準備中です。原文の説明を表示しています。

Recommends early delivery based on individualized risk assessment rather than expectant management for pregnant patients with preexisting diabetes mellitus (PDM). Consider when evaluating delivery timing in the presence of diabetes‑related complications, suboptimal glycemia, abnormal fetal growth, or maternal comorbidities that may increase perinatal risk beyond 38 weeks gestation.

日本語の概要は準備中です。原文の説明を表示しています。

This skill recommends obtaining serum free T4 and prolactin levels within 1–2 weeks after transsphenoidal surgery (TSS) for Cushing's syndrome to screen for overt hypopituitarism. Use in postoperative Cushing's syndrome patients during the early recovery window when evaluating for new pituitary hormone deficiencies.

日本語の概要は準備中です。原文の説明を表示しています。

This skill recommends unilateral resection by an experienced adrenal surgeon for all cases of benign unilateral disease causing Cushing's syndrome. Trigger when a CS patient has a unilateral adrenal lesion confirmed benign via imaging and biochemical assessment.

日本語の概要は準備中です。原文の説明を表示しています。

This skill recommends obtaining a postoperative pituitary MRI within 1–3 months after successful transsphenoidal surgery (TSS) to establish a new baseline for future recurrence assessment. Use when a Cushing’s syndrome patient has achieved biochemical remission post‑TSS and is entering routine follow‑up.

日本語の概要は準備中です。原文の説明を表示しています。

This skill recommends follow-up morning cortisol and/or ACTH stimulation tests or insulin-induced hypoglycemia to assess HPA axis recovery in postoperative Cushing's syndrome patients with at least one intact adrenal gland. Triggers include postoperative remission (morning cortisol <5 µg/dL or UFC <28–56 nmol/d) and the need to evaluate HPA recovery before glucocorticoid discontinuation.

日本語の概要は準備中です。原文の説明を表示しています。

Monitors glucocorticoid replacement in primary adrenal insufficiency (PAI) patients using clinical assessment of body weight, postural blood pressure, energy levels, and signs of frank glucocorticoid excess. Trigger phrases include "PAI patient on glucocorticoid replacement," "assess for weight gain or insomnia," and "evaluate for postural hypotension or fatigue."

日本語の概要は準備中です。原文の説明を表示しています。

This skill outlines monitoring glucocorticoid replacement in children with primary adrenal insufficiency (PAI) using clinical assessment of growth velocity, weight, blood pressure, and energy levels. Trigger when evaluating a child with PAI for adequacy of glucocorticoid therapy during routine follow-up.

日本語の概要は準備中です。原文の説明を表示しています。

This skill outlines monitoring of mineralocorticoid replacement in primary adrenal insufficiency, focusing on clinical assessment of salt craving, postural hypotension, or edema alongside serum electrolyte measurements. It is initiated when evaluating patients on fludrocortisone therapy to ensure adequate dosing and avoid over- or under-replacement.

日本語の概要は準備中です。原文の説明を表示しています。

Recommends performing biochemical testing for HPA axis at least 18-24 hours after last hydrocortisone dose or longer for synthetic glucocorticoids. Use when scheduling HPA axis testing in glucocorticoid-treated patient needing assessment of adrenal reserve.

日本語の概要は準備中です。原文の説明を表示しています。

Calculate and interpret the PREVENT-ASCVD risk score (10-year and 30-year) for primary prevention of atherosclerotic cardiovascular disease per the 2026 ACC/AHA multisociety dyslipidaemia guideline. Covers inputs required, risk-category thresholds (low <3%, borderline 3–<5%, intermediate 5–<10%, high ≥10%), when to use the 30-year calculation (adults 30–59), and how PREVENT differs from the older Pooled Cohort Equations (lower risk estimates by 40–50%, race-agnostic). Use when a clinician asks what the 10-year ASCVD risk is, how to calculate PREVENT, PCE vs PREVENT, risk category for this patient, does my patient need a statin, 30-year risk calculation, primary prevention risk assessment. Grounded in the 2026 ACC/AHA multisociety dyslipidaemia guideline.

日本語の概要は準備中です。原文の説明を表示しています。

Guide a non-stigmatising pediatric obesity consultation using the 5As framework (Ask, Assess, Advise, Agree, Assist) and 4Ms assessment (Metabolic, Mechanical, Mental Health, Social Milieu), based on the CMAJ 2025 guideline. Trigger when a clinician asks how to approach a weight conversation with a child or family, how to use the 5As for obesity, how to assess a child with obesity, or how to conduct a non-judgmental obesity visit.

日本語の概要は準備中です。原文の説明を表示しています。

Comprehensive REST API design review with automated linting, breaking-change detection, and design scorecards. Catches inconsistent conventions, missing versioning, and design smells before APIs ship. Use when reviewing a PR that adds or changes API endpoints, auditing an existing API for v2 migration, or establishing API standards for a team.

日本語の概要は準備中です。原文の説明を表示しています。

Testing and benchmarking LLM agents including behavioral testing, capability assessment, reliability metrics, and production monitoring—where even top agents achieve less than 50% on real-world benchmarks

日本語の概要は準備中です。原文の説明を表示しています。

This skill should be used when the user asks to "implement LLM-as-judge", "compare model outputs", "create evaluation rubrics", "mitigate evaluation bias", or mentions direct scoring, pairwise comparison, position bias, evaluation pipelines, or automated quality assessment.

日本語の概要は準備中です。原文の説明を表示しています。

Analyze the current uncommitted diff and give a detailed summary with risk assessment. Use when asking what changed, reviewing changes before a commit, or requesting a change summary.

日本語の概要は準備中です。原文の説明を表示しています。

Expert-level clinical engineering covering medical equipment management, hospital technology systems, healthcare IT integration, safety standards, and health technology assessment.

日本語の概要は準備中です。原文の説明を表示しています。

Phase exécution. Détecte le mode (epic/task/bug) selon le type d'issue et lance le bon mécanisme : loop driver background pour epic, code-dev synchrone pour task/bug. Usage: /implement <issue#>

日本語の概要は準備中です。原文の説明を表示しています。

Code comment accuracy verification, documentation completeness assessment, comment rot detection.

日本語の概要は準備中です。原文の説明を表示しています。

Code comment accuracy verification, documentation completeness assessment, comment rot detection.

日本語の概要は準備中です。原文の説明を表示しています。

Write clean, readable, and maintainable code following principles from Robert C. Martin's "Clean Code" and Object Calisthenics. Use when writing, reviewing, or refactoring code to improve naming, function design, formatting, error handling, and class structure. Includes code smell detection and refactoring guidance.

日本語の概要は準備中です。原文の説明を表示しています。

Creates marketing analytics reports, KPI dashboards, ROI calculations, and performance summaries for SME marketing teams. Handles weekly/monthly reporting, campaign analysis, content performance reviews, and data-driven recommendations. Use when user asks about marketing metrics, reporting, KPIs, dashboards, ROI analysis, performance review, or data-driven marketing decisions.

日本語の概要は準備中です。原文の説明を表示しています。

Creates ad copy, Google Ads RSA headlines, A/B test plans, and campaign analysis for SME performance marketing. Handles paid search, paid social, email campaigns, and SEO content. Use when user asks about ads, campaigns, Google Ads, paid media, SEO, conversion optimization, or marketing performance metrics.

日本語の概要は準備中です。原文の説明を表示しています。